LearnGlossaryMarketStocksSuperinvestorsSign in

AVTX

Avalo Therapeutics, Inc.

Healthcare · $800M market cap

Verdict

We can't put a fair value on AVTX right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-51.1% a year✗
Sales growth-28.1% a year✗
Free cash flow growth—?
Return on invested capital-39.2%✗

Follow AVTX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 10, 2026: no open-market purchases, 1 sale worth $179K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Sullivan Christopher Ryan

Chief Financial Officer · 2026-09-10

Sold

$179K

Other filings

Sullivan Christopher Ryan

Chief Financial Officer · 2026-09-10

Option exercise

$82K

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works